dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ljungman, Per |
dc.contributor.author | de la Camara, Rafael |
dc.contributor.author | MIKULSKA, MALGORZATA |
dc.contributor.author | Tridello, Gloria |
dc.contributor.author | Aguado , Beatriz |
dc.contributor.author | Alzahrani, Mohsen |
dc.contributor.author | Fox, Maria Laura |
dc.date.accessioned | 2022-06-09T07:38:33Z |
dc.date.available | 2022-06-09T07:38:33Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021 Oct;35:2885–2894. |
dc.identifier.issn | 1476-5551 |
dc.identifier.uri | https://hdl.handle.net/11351/7652 |
dc.description | Haematological diseases; Infectious diseases; COVID-19 |
dc.description.abstract | This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Leukemia;35 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Sang - Malalties |
dc.subject | COVID-19 (Malaltia) - Complicacions |
dc.subject | Cèl·lules mare hematopoètiques - Trasplantació |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Surveys and Questionnaires |
dc.title | COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41375-021-01302-5 |
dc.subject.decs | trasplante de células madre hematopoyéticas |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | encuestas y cuestionarios |
dc.relation.publishversion | https://doi.org/10.1038/s41375-021-01302-5 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. [de la Camara R] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Mikulska M] Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy. [Tridello G] Pediatric Hematology Oncology, Verona, Italy. [Aguado B] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Zahrani MA] King Abdul – Aziz Medical City, Riyadh, Saudi Arabia. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34079042 |
dc.identifier.wos | 000657226100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |